The CDMO Reckoning: 2026 - Why Capacity No Longer Wins
Capacity used to be the product. This report sets out why that stopped being true in 2026, as the BIOSECURE Act, GLP-1 volume and ADC complexity split the market into a commoditised middle and a sovereign premium, and argues the binding constraint is now leadership rather than square footage.
What this report answers
- What does the BIOSECURE Act actually change for a molecule entering Phase II now, given the grandfathering clause runs to 2032?
- Where is the revenue leaving Chinese CDMOs going, and which regions are set up to absorb it?
- Is the GLP-1 bottleneck still sterile fill-finish, or has it already moved somewhere else?
- Why do ADC programmes keep failing upstream of the conjugation suite?
- What are private equity sponsors doing with CDMO assets they cannot exit through an IPO?
- Which roles decide whether a new facility executes, and why are they so hard to fill?
200%
the year-over-year rise in demand for digital twin architects that ProGen Search records in the report, used as evidence that the operating model on the manufacturing floor has already shifted.
40%
the increase in mandates for team lift-outs in the viral vector space that ProGen Search reports, which the analysis reads as employers paying to buy a working unit rather than assemble one.
What the analysis establishes
The geopolitical divide after BIOSECURE
The report treats the BIOSECURE Act as settled law rather than a pending risk, and works through what a grandfathering clause actually means for a molecule entering the clinic now. It maps where displaced work is going, which regions are competing on what basis, and the sourcing model it expects sponsors to adopt in response.
Where the modality bottlenecks actually sit
Two modalities are pulling capacity in different directions. The report separates the volume problem in GLP-1 agonists from the complexity problem in antibody-drug conjugates, identifies where each one actually binds rather than where the industry has been building, and explains why apparent relief in one unit operation moves the constraint upstream instead of removing it.
The private equity exit supercycle
A vintage of assets bought during the pandemic build-out is reaching the end of its hold period into narrower exit paths. The report sets out how sponsors are responding, uses one European breakup as its worked case study, and describes the valuation spread between commoditised and complex capability without treating scale as the variable that explains it.
The talent and intelligence gap
This is the chapter the rest of the report is built to reach. It names the layer of leadership that governs whether a facility executes, explains why the required skill profile has moved faster than the workforce has, and describes the mechanism by which process knowledge leaves a site without anyone recording that it has gone.
Digital operations and the licence to operate
Digital twins, continuous manufacturing and mandatory Scope 3 reporting are treated as operating requirements rather than initiatives. The report sets out what each one changes about how a site is run and staffed, and why procurement teams have started applying a test that sits alongside the certificate of analysis rather than inside it.
How it was built
Built from three inputs the report is explicit about: publicly available market data, aggregated and anonymised observations from ProGen Search active executive search mandates, and comparative inference across the CDMO and pharmaceutical sectors. The report states plainly that its market projections, valuation multiples and talent-gap analyses are modelled planning ranges rather than guaranteed outcomes, and the forward calls in each chapter are labelled as ProGen Search predictions rather than presented as consensus.
Written for private equity sponsors holding or underwriting CDMO assets, CDMO boards and chief executives, and pharma sourcing and manufacturing leaders deciding where commercial supply should sit.
Contents
- The End of Geopolitical Agnosticism
- Executive Summary: The State of the Union 2026
- Chapter 1: The Geopolitical Divide
- Chapter 2: The Modality Wars
- Chapter 3: Financials and M&A
- Chapter 4: The Talent and Intelligence Gap
- Chapter 5: Future Tech and Sustainability
- Conclusion: Strategic Advice for CDMO CEOs
Organisations and agencies referenced
Aragen, Biocon, Blue Wolf Capital, Carbogen Amcis, Catalent, Department of Defense, Eli Lilly, EQT, FDA, Fujifilm Diosynth, Lonza, Novo Holdings, Novo Nordisk, PCI Pharma Services, Recipharm, Samsung Biologics, Sanofi, Simtra, Sterling Pharma Solutions, Syngene, Thermo Fisher, WuXi XDC
The full 11-page briefing is free. Tell us where to send it and it downloads immediately.
Weaponised Capacity: The CDMO Report 2026
The paid CDMO report goes considerably further than this briefing: full sector structure, named operators, and where schedulable Western capacity actually sits.
See the full report →